US Patent

US12453712 — Antitumoral use of cabazitaxel

Method of Use · Assigned to Sanofi Mature IP · Expires 2030-10-27 · 4y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of cabazitaxel in combination with prednisone or prednisolone for treating metastatic prostate cancer.

USPTO Abstract

The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Drugs covered by this patent

Jevtana Kit (cabazitaxel) · Accord Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4334`	—	Jevtana Kit

Patent Metadata

Patent number: US12453712
Jurisdiction: US
Classification: Method of Use
Expires: 2030-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Mature IP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.